DEXILANT SOLUTAB
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Approved
Jan 2016
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEXILANT SOLUTAB is an orally disintegrating delayed-release tablet formulation of dexlansoprazole, a proton pump inhibitor (PPI) approved in January 2016. The product treats acid-reflux disorders by reducing gastric acid production through inhibition of the proton pump in parietal cells. This formulation is designed for patients who have difficulty swallowing conventional tablets.
LOE Approaching2.8 years to LOE
The product is approaching loss of exclusivity (2029), signaling a contracting commercial footprint and likely right-sizing of brand team resources over the next 2-3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on DEXILANT SOLUTAB at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.